Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Update

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 328,100 shares, an increase of 19.2% from the April 15th total of 275,200 shares. Approximately 0.5% of the company's stock are short sold. Based on an average daily volume of 391,900 shares, the short-interest ratio is presently 0.8 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a report on Tuesday.

Cardiol Therapeutics Stock Performance

Shares of Cardiol Therapeutics stock remained flat at $2.18 on Tuesday. 352,593 shares of the stock were exchanged, compared to its average volume of 359,085. Cardiol Therapeutics has a twelve month low of $0.55 and a twelve month high of $2.25. The business has a fifty day moving average price of $1.78 and a 200-day moving average price of $1.31. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $148.85 million, a PE ratio of -6.61 and a beta of 0.87.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last released its earnings results on Monday, April 1st. The company reported ($0.09) earnings per share for the quarter. As a group, equities analysts forecast that Cardiol Therapeutics will post -0.25 earnings per share for the current fiscal year.

Institutional Trading of Cardiol Therapeutics

An institutional investor recently raised its position in Cardiol Therapeutics stock. Tejara Capital Ltd increased its position in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) by 29.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 645,457 shares of the company's stock after buying an additional 148,396 shares during the quarter. Tejara Capital Ltd owned 1.00% of Cardiol Therapeutics worth $578,000 at the end of the most recent quarter. Institutional investors own 12.49% of the company's stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.